KALV – kalvista pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan [Yahoo! Finance]
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
Form 4 KalVista Pharmaceuticals For: Apr 09 Filed by: VHCP Co-Investment Holdings III, LLC
Form 8-K KalVista Pharmaceuticals For: Apr 08
Form 8-K KalVista Pharmaceuticals For: Mar 13
Form 8-K KalVista Pharmaceuticals For: Mar 12
Form 10-Q KalVista Pharmaceuticals For: Jan 31
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.